| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 02/12/2024 | 18:00 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:XCUR | Exicure Inc |
| 29/11/2024 | 23:51 | Edgar (US Regulatory) | Form SC 13D - General Statement of Acquisition of Beneficial Ownership | NASDAQ:XCUR | Exicure Inc |
| 29/11/2024 | 23:38 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:XCUR | Exicure Inc |
| 26/11/2024 | 22:36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:XCUR | Exicure Inc |
| 25/11/2024 | 22:27 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:XCUR | Exicure Inc |
| 22/11/2024 | 22:30 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:XCUR | Exicure Inc |
| 14/11/2024 | 22:38 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:XCUR | Exicure Inc |
| 14/11/2024 | 22:01 | Business Wire | Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results | NASDAQ:XCUR | Exicure Inc |
| 19/09/2024 | 12:26 | IH Market News | AIG names new CFO; Progyny Drops 24% After Losing Key 2025 Contract; Exicure Jumps 190% With Nasdaq Extension | NASDAQ:XCUR | Exicure Inc |
| 18/09/2024 | 22:01 | Business Wire | Exicure, Inc. Receives Extension from Nasdaq Hearings Panel | NASDAQ:XCUR | Exicure Inc |
| 17/09/2024 | 03:38 | Edgar (US Regulatory) | Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:XCUR | Exicure Inc |
| 10/09/2024 | 00:53 | Business Wire | Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation | NASDAQ:XCUR | Exicure Inc |
| 26/08/2024 | 15:08 | Business Wire | Exicure, Inc. Announces 1-for-5 Reverse Stock Split | NASDAQ:XCUR | Exicure Inc |
| 19/08/2024 | 16:31 | Business Wire | Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting | NASDAQ:XCUR | Exicure Inc |
| 15/08/2024 | 16:31 | Business Wire | Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting | NASDAQ:XCUR | Exicure Inc |
| 13/08/2024 | 22:01 | Business Wire | Exicure, Inc. Reports Second Quarter 2024 Financial Results | NASDAQ:XCUR | Exicure Inc |
| 08/08/2024 | 22:27 | Business Wire | Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics | NASDAQ:XCUR | Exicure Inc |
| 01/08/2024 | 22:01 | Business Wire | Exicure, Inc. Receives Positive Listing Determination from Nasdaq | NASDAQ:XCUR | Exicure Inc |
| 17/06/2024 | 22:01 | Business Wire | Exicure, Inc. Reports First Quarter 2024 Financial Results | NASDAQ:XCUR | Exicure Inc |
| 11/06/2024 | 23:18 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:XCUR | Exicure Inc |
| 06/06/2024 | 22:23 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:XCUR | Exicure Inc |
| 06/06/2024 | 22:17 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] | NASDAQ:XCUR | Exicure Inc |
| 06/06/2024 | 22:01 | Business Wire | Exicure, Inc. Reports Full Year 2023 Financial Results | NASDAQ:XCUR | Exicure Inc |
| 23/05/2024 | 22:01 | Business Wire | Exicure, Inc. Received Nasdaq Notice of a Delisting Determination | NASDAQ:XCUR | Exicure Inc |
| 16/05/2024 | 22:08 | Business Wire | Exicure, Inc. Reports Third Quarter 2023 Financial Results | NASDAQ:XCUR | Exicure Inc |
| 15/05/2024 | 22:45 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:XCUR | Exicure Inc |
| 22/04/2024 | 22:01 | Business Wire | Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K | NASDAQ:XCUR | Exicure Inc |
| 04/03/2024 | 23:37 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:XCUR | Exicure Inc |
| 05/02/2024 | 22:01 | Business Wire | Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis | NASDAQ:XCUR | Exicure Inc |
| 28/11/2023 | 22:01 | Business Wire | Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | NASDAQ:XCUR | Exicure Inc |